Фактор риска
Незначительная волатильность
Фактор доходности
Недооценена
О компании
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
Оценка компании
Как с исторической, так и с прогнозной точек зрения акции недооценены по сравнению с аналогичными акциями. В частности, акция компании недооценена по P/E, «дешевая» по EV
Прогноз аналитиков
Средняя целевая цена HLUN-B.CO составляет 45, таким образом потенциал роста составляет 9%. Обычно это означает рекомендацию «ДЕРЖАТЬ» среди инвестиционных компаний. Эта н